Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future

doi:10.3748/wjg.v29.i34.5020

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3082)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

1985

Tables (1-3)

321

Sum=2399

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

207

Sum=303

Publishing Process of This Article

Item

Count

Browse

Download

144

Sum=227

Sep 14, 2023 (publication date) through May 23, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Sep 14, 2023; 29(34): 5020-5037
Published online Sep 14, 2023. doi: 10.3748/wjg.v29.i34.5020

Table 3 Clinical trials of adjuvant immunotherapy for resectable esophageal squamous cell carcinoma

Drug	Trial name/No.	Phase	Sample size	Clinical stage	Design	Chemotherapy drugs	Chemotherapy cycles	Radiotherapy	Interval time to surgery	Primary endpoint	Start date	Outcome
Nivolumab	CheckMate-577/NCT02743494	III	784 (ESCC29%)	NA	Two-arm	NA				DFS	Completed	22.1:11.0 mo
Toripalimab (+ Neoadjuvant)	NCT 04437212	II	20	IIB-IVA	Single-arm	PTX + DDP	5, Q3W	41.4 Gy/23 f	6-8 wk	MPR	Jul 1, 2020
Tislelizumab	AIRE/ChiCTR2100045651	III	110	High-risk resected locally advanced	Two-arm	Platinum-based doublets	2, Q3W			DFS	May 1, 2021
Tislelizumab	CRISEC/NCT04776590	II	30	NA	Single-arm	PTX + CBP	5, Q1W	41.4 Gy/23 f		pCR	Jan 28, 2021

DFS: Disease-free survival; NA: Not available; DDP: Cisplatin; PTX: Paclitaxel; CBP: Carboplatin; pCR: Pathological complete response; MPR: Major pathological response.

Citation: Liu Y. Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future. World J Gastroenterol 2023; 29(34): 5020-5037
URL: https://www.wjgnet.com/1007-9327/full/v29/i34/5020.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i34.5020